A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma

Published:2017-10-25 Issue:7 Volume:59 Page:1666-1671
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Patel Pritesh¹²,Oh Annie L.¹,Koshy Matthew²³⁴,Sweiss Karen²⁵,Saraf Santosh L.¹²,Quigley John G.¹²,Khan Irum¹²,Mahmud Nadim¹²,Hacker Eileen²⁶,Ozer Howard¹²,Peace David J.¹²,Weichselbaum Ralph R.³⁴,Aydogan Bulent³⁴,Rondelli Damiano¹²

Affiliation:

1. Division of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA;

2. University of Illinois Cancer Center, Chicago, IL, USA;

3. Department of Radiation Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA;

4. Department of Cellular and Radiation Oncology, University of Chicago, Chicago, IL, USA;

5. Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA;

6. Department of Biobehavioural Health Science, College of Nursing, University of Illinois at Chicago, Chicago, IL, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1390231

Reference37 articles.

1. Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

2. Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial

3. How we manage autologous stem cell transplantation for patients with multiple myeloma

4. Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant

5. Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High dose total marrow irradiation (TMI) does not increase long‐term toxicity of myeloablative fludarabine/busulfan (FluBu4) conditioning regimen in allogeneic hematopoietic stem cell transplantation (HSCT);European Journal of Haematology;2024-04-02

2. Radiotherapy in the Conditioning Regimen of Allogeneic Hematopoietic Stem Cell Transplant: Rational, Clinical Implications and Technical Aspects;Comprehensive Hematology and Stem Cell Research;2024

3. Melphalan-loaded methoxy poly(ethylene glycol)-poly(d,l-lactide) copolymer nanomicelles in the treatment of multiple myeloma;Chinese Chemical Letters;2023-09

4. Total marrow irradiation in hematopoietic stem cell transplantation for hematologic malignancies;Frontiers in Medicine;2023-04-20

5. Phase 1 Study of the Combination of Escalated Total Marrow Irradiation Using Helical Tomotherapy and Fixed High-Dose Melphalan (140 mg/m²) Followed by Autologous Stem Cell Transplantation at First Relapse in Multiple Myeloma;International Journal of Radiation Oncology*Biology*Physics;2023-03